The Science of MDMA & Its Therapeutic Uses: Benefits & Risks | Huberman Lab Podcast

Introduction

In this section, Andrew Huberman introduces the topic of MDMA and its properties. He explains how it is similar to methamphetamine but also distinct from it due to its effects on dopamine and serotonin.

What is MDMA?

• MDMA stands for methylene dioxy methamphetamine.

• It powerfully promotes the release of dopamine and controls the release of serotonin.

• It is a stimulant that acts as an empathogen, increasing social connectedness and empathy.

Recreational vs Therapeutic Use

• MDMA is commonly used as a recreational drug but is also being tested in clinical trials for its use as an empathogen for the treatment of PTSD.

• There is a distinct difference between recreational and therapeutic use of MDMA.

Legality

• As of June 2023, MDMA is still a schedule one drug that is highly illegal to possess or sell in the United States.

Path to Legality

In this section, Andrew Huberman discusses the path to legality for MDMA. He talks about why it became illegal and what needs to happen for it to become legal again.

History of MDMA

• In the 1970s, MDMA was used therapeutically by psychiatrists before becoming popular as a recreational drug in the 1980s.

• Due to concerns about its safety, it was made illegal in 1985.

Current Status

• Currently, there are efforts underway to legalize MDMA for therapeutic use through clinical trials.

Future Possibilities

• If these clinical trials continue to show positive results, there may be a path towards legalization for therapeutic use.

Clinical Trials

In this section, Andrew Huberman discusses clinical trials using MDMA for PTSD treatment. He talks about their success rates and how they differ from other treatments.

Success Rates

• The field of psychiatry has never before seen the kind of success in treatment of PTSD with any other compound that they are seeing and achieving with the appropriate safe use of MDMA.

• Clinical trials using MDMA for the treatment of PTSD are achieving incredible early results.

Therapeutic Use

• MDMA is used therapeutically in conjunction with nine therapy sessions.

• It is a distinct category of compound from either classic psychedelics like psilocybin or LSD which largely work on the serotonin system and tend to produce mystical experiences.

Toxicity

In this section, Andrew Huberman discusses the toxicity of MDMA. He talks about its potential neurotoxicity and ways to avoid it.

Potential Neurotoxicity

• Due to its similarity to methamphetamine, which is highly neurotoxic, MDMA can be neurotoxic as well.

• There are still questions about its toxicity and long-term effects both after acute use meaning just one to three times as well as chronic use meaning people who have taken it many many times.

Safe Use

• There are ways to use MDMA therapeutically that avoid its toxicity.

• Spacing between sessions of MDMA and dosages can help offset some of the potential toxicity.

Conclusion

In this section, Andrew Huberman concludes his discussion on MDMA. He emphasizes that this podcast is separate from his teaching and research roles at Stanford. He also thanks sponsors for supporting his efforts to bring science-related tools to the general public.

Final Thoughts

• By the end of today's discussion, listeners will have a thorough understanding of what MDMA is, what it isn't, what is known about what it does, what is known about what it doesn't do, as well as some outstanding questions about MDMA that remain unresolved.

• This podcast is part of Andrew Huberman's effort to bring zero cost to consumer information about science and science-related tools to the general public.

Sponsorship

• The sponsors of today's podcast are Helix Sleep, which makes mattresses and pillows tailored to unique sleep needs.

Upgrading Your Mattress

The importance of sleep and how upgrading your mattress can help improve the quality of your sleep.

Benefits of a Good Mattress

• Consistent good sleep is important for overall well-being.

• Helixsleep.com offers customized mattresses to match individual needs.

• Get up to $350 off on all mattress orders and two free pillows by taking their two-minute sleep quiz.

Roca Eyeglasses and Sunglasses

The benefits of Roca eyeglasses and sunglasses designed with performance in mind.

Features of Roca Eyewear

• Designed with performance in mind, especially for sports.

• Lightweight design that won't slip off when sweaty.

• Includes styles that are suitable for recreational use as well.

• Visit roka.com and enter code huberman at checkout to save 20% on your order.

HVMN Ketone IQ Supplement

How HVMN Ketone IQ supplement can increase blood ketones, leading to improved brain function and energy levels.

Benefits of HVMN Ketone IQ Supplement

• Increases blood ketones even if not following a ketogenic diet.

• Improves brain function and energy levels during cognitive work or workouts.

• Visit hvmn.com/huberman to save 20% on your order.

MDMA: A Unique Compound with Fascinating History

The history, chemical structure, subjective effects, and potential clinical utility of MDMA.

History and Chemical Structure

• Synthesized by Merck in the early 1900s but never applied to any particular clinical use.

• Rediscovered by Alexander Shulgin, a renegade drug chemist who explored subjective effects of different drugs on humans.

• Unlike other similar compounds found in nature or pharmaceutical industry shelf, MDMA is a unique synthetic compound.

Subjective Effects and Clinical Utility

• Produces unique subjective effects that make it an exciting compound for potential clinical treatment.

• Increases blood ketones even if not following a ketogenic diet.

The History of MDMA and Its Legal Status

This section discusses the history of MDMA, its synthesis, and the book "Pikal" that describes Shogun's discovery of MDMA. It also touches on the current legal status of MDMA and its potential neurotoxicity.

The Book "Pikal"

• "Pikal" is a book written by Shogun that describes his discovery of MDMA.

• It also includes the synthesis of MDMA, which made it unavailable for a long time.

• The book is now available again in both printed and audible form.

The Importance of Understanding the History of MDMA

• Understanding the history of MDMA is important because it sheds light on the pharmaceutical industry's history, the War on Drugs in the United States, and how illegal drug exploration interacts with drugs for clinical treatment.

• Currently, MDMA has breakthrough status, meaning scientists and clinicians can study it if they have authorization to do so.

• However, it is still a Schedule I drug and illegal to possess unless granted permission to study in a clinical or laboratory setting.

Potential Neurotoxicity

• There are concerns about potential neurotoxicity associated with MDMA use.

• It has been hypothesized that it may kill neurons of serotonin and dopamine types.

• Loss of dopamine neurons is linked to Parkinson's Disease while loss of serotonergic neurons negatively impacts mood regulation.

Race in Scientific Community

• There are two groups in the scientific community racing to establish either toxicity or utility/lack thereof regarding MDMA use.

• One group aims to prevent its legalization while another group aims to establish its usefulness for treating PTSD.

What is MDMA?

This section provides an overview of what MDMA is and how it affects the brain.

Definition

• MDMA stands for 3,4-methylenedioxy-methamphetamine.

• It belongs to the category of drugs called phenylethylamines.

Methamphetamine Component

• The methamphetamine component in MDMA blocks the reuptake of dopamine from neurons after dopamine is released.

• This creates net increases in dopamine levels.

Neurotransmitters and Neuromodulators

• Neurons release chemicals at their sites of communication called synapses.

• Synapses are little gaps between neurons where neurotransmitters or neuromodulators are released.

• Dopamine is a neuromodulator that can modulate the activity of other neurons by either increasing or decreasing their activity.

Mechanisms of Drugs like Adderall and Vyvanse

• Drugs like Adderall and Vyvanse are amphetamines that have either quick or long releases.

• They work by blocking the reuptake of dopamine from neurons after its release, leading to net increases in dopamine levels.

How MDMA Affects Neurotransmitters

In this section, the speaker explains how MDMA affects neurotransmitters in the brain.

MDMA's Effect on Dopamine

• MDMA prevents the reuptake of dopamine by blocking dopamine transporters.

• As a result, more dopamine is available in the synapse to bind to receptors once they become available.

• The methamphetamine component of MDMA interferes with the repackaging of dopamine into vesicles, leading to a buildup of dopamine in presynaptic neurons.

• When an electrical impulse comes down that neuron and dopamine is released, a huge amount of dopamine is released, leading to enormous increases in dopaminergic tone or drive.

MDMA's Effect on Serotonin

• MDMA leads to huge increases in serotonin by blocking serotonin transporters and interfering with the packaging of serotonin into vesicles.

• This causes a big buildup of serotonin in presynaptic terminals and massive increases in serotonin release.

• The combination of big increases in both dopamine and serotonin leads to highly unusual effects that seem potentially clinically beneficial.

Effects on Mood Elevation and Social Connection

• The increase in dopaminergic tone from MDMA causes people to feel alert, talkative, excited, and motivated.

• By also causing big increases in serotonin, it activates neural networks associated with feeling socially connected.

• People who have taken MDMA look at faces that ordinarily they would rate as fearful and rate them as less fearful. They see faces that are smiling.

The Biology of MDMA

In this section, the speaker discusses the biology of MDMA and how it differs from other compounds referred to as psychedelics.

MDMA vs. Other Psychedelics

• MDMA causes big increases in dopamine and even bigger increases in serotonin.

• Psilocybin and LSD mainly increase serotonin activation in the brain, while ketamine is a dissociative anesthetic.

• Ketamine is being used for the treatment of depression and is currently legal.

• Researchers consider MDMA to be an empathogen or an actogen rather than a psychedelic due to its lack of visual or auditory hallucinations.

Unique Effects of MDMA

• The combination of big increases in dopamine and even bigger increases in serotonin creates a situation where people have more energy without feeling irritated.

• MDMA produces a sense of emotional warmth towards others and oneself, increasing trust which makes talk therapy for PTSD much more effective.

The Role of MDMA in Treating PTSD

In this section, the speaker discusses how MDMA can augment or boost the effects of talk therapy for PTSD.

How MDMA Helps with PTSD

• Taking MDMA on its own does not cure PTSD but can make talk therapy much more effective.

• The major effect of MDMA for treating PTSD is to increase trust between patients and therapists, allowing them to better process traumatic experiences.

Mechanisms of Psilocybin, LSD, and MDMA

In this section, the speaker discusses how psilocybin, LSD, and MDMA affect the brain.

Psilocybin and LSD

• Psilocybin and LSD mimic serotonin closely.

• They selectively activate the serotonin 2A receptor (5ht2a).

• This leads to more interconnectedness between different brain areas.

• It also opens up neuroplasticity or rewiring of neural connections that persist long after the effects have worn off.

MDMA

• MDMA activates the serotonin 1B receptor.

• This creates a strong impact on neural circuits related to trust and social engagement.

• It increases dopamine in the brain which makes people motivated to do something.

• Increases in serotonin acting on the serotonin 1B receptor create a desire to bond or create trust.

• Under the influence of MDMA, people are far more willing to trust therapists and themselves when exploring challenging things.

Trauma and PTSD Treatment with MDMA

In this section, the speaker talks about trauma and how it relates to PTSD treatment with MDMA.

Trauma

• Trauma fundamentally changes how our brain works for the worse.

• Events that change how we think emotionally or behave going forward in ways that are not adaptive define trauma.

PTSD Treatment with MDMA

• Under the influence of parallel increases in dopamine and serotonin, people are far more willing to trust therapists and themselves when exploring challenging things.

• Quality MDMA therapy consists of having a good rapport with the therapist guiding PTSD treatment and engaging in conversations with oneself.

• The direct application of MDMA for the treatment of PTSD will be discussed later.

Brain Circuits Activated by MDMA

In this section, the speaker discusses what MDMA does in the brain both in the short term and long term.

Short Term Effects

• Increases in trust, pleasure, energy, and emotional warmth are subjective changes that occur under the influence of MDMA.

Long Term Effects

• Neuroplastic or rewiring changes produced by MDMA can be beneficial or not beneficial.

• Understanding neural circuit phenomena is necessary before considering clinical findings.

Conclusion

The speaker discusses how psilocybin, LSD, and MDMA affect the brain. Psilocybin and LSD mimic serotonin closely while selectively activating 5ht2a receptors leading to more interconnectedness between different brain areas. On the other hand, MDMA activates serotonin 1B receptors creating a strong impact on neural circuits related to trust and social engagement. Trauma fundamentally changes how our brain works for the worse while events that change how we think emotionally or behave going forward define trauma. Under parallel increases in dopamine and serotonin under the influence of MDMA people are far more willing to trust therapists when exploring challenging things. Finally, understanding neural circuit phenomena is necessary before considering clinical findings.

Athletic Greens and Understanding the Effects of MDMA on the Brain

In this section, Dr. Huberman talks about how to mix Athletic Greens while traveling and provides a link for a special offer. He then discusses different experiments that can be done to understand the effects of MDMA on the brain.

Understanding the Effects of MDMA on the Brain

• Resting State Functional Connectivity: One way to study the effects of MDMA is by putting someone who has never ingested it into an fmri machine and measuring their resting state functional connectivity.

• Default Mode Network (DMN): The DMN is active in our brains when we aren't attending to anything specific outside us. It relates to our sense of imagination, daydreaming, and self-referencing.

• Different Dosages and Stimuli: Studies have been done where people are given different dosages of MDMA and presented with stimuli such as happy or sad faces or images that recall memories of traumatic events.

• Pro-Social Effects in Animals: Studies have been done on laboratory mice and even cephalopods (octopuses, cuttlefish, etc.) showing that activation of more serotonin release in particular brain networks leads to pro-social effects.

Conclusion

Dr. Huberman outlines several ways in which researchers can study the effects of MDMA on the brain, including measuring resting state functional connectivity, studying the DMN, giving different dosages and stimuli, and observing pro-social effects in animals.

Effects of MDMA on Perception of Emotional Expressions

In this section, the speaker discusses a study that looked at how MDMA impacts people's perceptions of others' emotional expressions. The study found that when people are on MDMA, their response to threatening faces or other threatening stimuli is reduced, and it's reduced in a very specific way which is reductions in activity of the amygdala.

MDMA and Perception of Emotional Expressions

• The study entitled "Effects of MDMA on Sociability and Neural Responses to Social Threat and Social Reward" looked at how MDMA impacts people's perceptions of others' emotional expressions.

• When people are under the influence of MDMA, they tend to rate threatening faces as less threatening and happy faces as more kind or generous than they would when they are not on MDMA.

• The amygdala is a structure involved in threat detection systems or networks of the brain. Reductions in activity of the amygdala were observed when people were under the influence of MDMA.

• The dosages used in these neuroimaging studies range anywhere from 0.75 milligrams per kilogram to 1.5 milligrams per kilogram.

Dosages Used in Studies

• Typical dosages used in these neuroimaging studies range anywhere from 0.75 milligrams per kilogram to 1.5 milligrams per kilogram.

• Clinical studies explore both an initial dose of 1.5 milligrams per kilogram followed by a so-called booster dose about 90 minutes to two and a half hours into the session.

• Specific dosages taken during any one particular session are rarely discussed, but they are important to consider when discussing the toxicity of MDMA.

Bi-Directional Effect of MDMA

• MDMA has a bi-directional effect on our perception of others' emotions, making people more likely to rate something as positive if it's initially positive and less likely to rate a threatening face as more threatening.

• The study used faces that were not of people on MDMA, but rather people under the influence of MDMA rated in a subjective way the friendliness or level of threat that they detect in these facial expressions.

MDMA and PTSD: The Role of Interoception and the Insula

In this section, the speaker discusses the role of interoception and the insula in PTSD. They explain how people with PTSD have heightened connectivity between the amygdala and insula, which is responsible for our sense of interoception.

The Insula and Interoception

• The insula is a brain area that's important for interoception, which is one's perception of their feelings, both physical sensations and emotional states.

• Normally, we don't notice what's going on inside our bodies unless we direct our interceptive capacity to them.

• There's a balance between interoception (our focus on internal sensations) and exteriorception (our focus on things outside our body).

• The insula has a map of the complete body surface including internal organs. Stimulation of neurons in different parts of the insula can cause someone to feel sensations in different parts of their body.

Amygdala Connectivity in PTSD

• People with PTSD tend to have stronger connections between the amygdala (the threat detection center) and insula than those without PTSD.

• This heightened connectivity provides an explanation for why people with PTSD often feel discomfort or bodily sensations associated with negative memories.

• Functional imaging studies show that there are direct connections between the amygdala and insula.

MDMA Therapy for PTSD

• Studies have shown that 1.5 milligrams per kilogram of MDMA weakens connections between the amygdala and insula.

• This weakening of connections scales directly with the relief of symptoms from PTSD.

• Observing a patient's brain network before and after taking MDMA provides more powerful evidence than just observing changes in arbitrary units.

Understanding the Effects of MDMA on the Brain

In this section, Dr. Andrew Huberman discusses how MDMA impacts the brain and its potential therapeutic effects for PTSD.

The Amygdala and Insula Connection

• Reduction in connections between amygdala and insula is related to reduction in symptoms of PTSD.

• Reduction in connection scales with reduction in clinically relevant symptoms.

• Understanding this connection can provide a mechanistic framework for understanding PTSD and the effects of MDMA.

Differences Between MDMA and Classic Psychedelics

• Classic psychedelics create long-lasting changes that increase lateral connectivity between different areas of the neocortex.

• MDMA does not produce long-lasting increases in lateral connectivity but does change resting state functional connectivity within limbic structures associated with threat detection.

Short-Term and Long-Term Effects of MDMA

• People who take MDMA report marked increases in positive mood as well as decreased blood flow to threat detection centers like the amygdala and hippocampus.

• Changes in brain activity are pervasive over time, leading to lowered levels of threat detection, heightened levels of positivity, and more active pro-social components of the brain.

Dopamine and Serotonin Effects

• Animal model studies have explored which brain networks and chemicals (serotonin or dopamine) are responsible for motivational versus pro-social effects of MDMA.

Neuroplasticity and MDMA

In this section, Dr. Huberman discusses a study on the neural mechanisms of MDMA in mice and how it translates to humans.

Study on Neural Mechanisms of MDMA

• The study was done on mice but the circuits involved are highly conserved between mice and humans.

• The study found that MDMA causes the release of dopamine which establishes the rewarding effects of an experience.

• The activation of serotonin 1B receptor in the nucleus accumbens by MDMA leads to pro-social effects.

• The addition of a huge release of serotonin by MDMA increases empathy and sociability for oneself and with others.

Conclusion

• Dr. Huberman explains that social connection is strongly rewarded and reinforced making social connection more likely after taking MDMA.

• People who take MDMA in a clinical therapeutic setting for PTSD often report feeling more empathy and compassion for themselves during the session but also for long periods of time even indefinitely after the session.

MDMA and its Effects on the Brain

In this section, Dr. Huberman discusses the effects of MDMA on the brain and how it differs from other drugs that increase serotonin levels.

MDMA's Polypharmacology

• MDMA causes a big increase in serotonin and dopamine.

• Methamphetamine, which also increases dopamine, is not known to be a pro-social drug.

• The release of both serotonin and dopamine has distinctly different effects than if just one is increased.

• SSRIs, which dramatically increase serotonin levels, are not known to create even close to the same sorts of effects as MDMA.

Activation of Serotonin at Particular Receptors

• Human and animal studies show that giving someone an SSRI prior to taking MDMA blocks the pro-social and empathogenic effects of MDMA.

• It's really about raising levels of a particular neurochemical acting in particular receptors in particular brain areas.

• The activation of Serotonin at particular receptors in this case the serotonin 1B receptor in particular brain areas largely explains the effects of MDMA.

Nucleus Accumbens

• The nucleus accumbens is part of that mesolimbic reward pathway that is essentially establishing a reward for whatever is happening at the moment.

• Conceptualize MDMA as an empathogen for which empathy and social connection are very strongly reinforced while under the influence of the drug.

Oxytocin Release

• Studies show that MDMA profoundly increases levels of oxytocin release in the brain.

• Oxytocin is considered a neuro hormone because it acts as both a neurotransmitter and a hormone.

The Role of Oxytocin in Bonding and Breakups

In this section, the speaker discusses the role of oxytocin in bonding between humans and other creatures, as well as the breaking of those bonds. The speaker also talks about how MDMA affects oxytocin release.

Oxytocin and Bonding

• Humans can have strong oxytocin responses to their pets, particularly dogs.

• Oxytocin is thought to be involved in bonding between people and other creatures.

• Increases in oxytocin levels cannot be directly related to any kind of direct experience of feeling bonded or not bonded.

MDMA and Oxytocin Release

• MDMA powerfully increases oxytocin release.

• People given 1.5 milligrams per kilogram of body weight of MDMA experienced significant changes in oxytocin levels.

• Dramatic increases in oxytocin that are very real when people take MDMA do not appear to underlie any of the known short or long-term subjective effects of MDMA such as sociability, empathy, etc.

The Effects of MDMA on Sociability

In this section, the speaker discusses how MDMA affects sociability and empathy.

Effects on Sociability

• A study found that increases in oxytocin produced by taking MDMA are not the source of the pro-social effects of MDMA.

• Increases in dopamine caused by taking MDMA increase motivation and reward serotonin activation associated with sociability.

• The dramatic increases in oxytocin produced by MDMA do not appear to underlie any of the known short or long-term subjective effects of MDMA such as sociability, empathy, etc.

Effects on Empathy

• No specific information provided in this section.

Conclusion

In this section, the speaker concludes that while the big increases in oxytocin produced by MDMA may not be directly related to the short and long-term effects of MDMA such as sociability and empathy, there could be other effects of oxytocin that we're just not aware of.

Final Thoughts

• The data from both animal models and humans point to the fact that the increases in oxytocin produced by MDMA are not directly related to any of the short and long-term effects of MDMA.

• It is unclear whether or not the big increase in oxytocin produced by MDMA is completely irrelevant in this context.

The Role of Oxytocin in MDMA's Effects

In this section, the speaker discusses the role of oxytocin in MDMA's effects on pro-sociability and empathy.

Oxytocin's Role

• While oxytocin has significant effects on our brains and bodies, it doesn't appear that the increases in oxytocin induced by MDMA have much to do with anything related to the value of MDMA as a treatment for PTSD or its subjective effects on empathy and sociability.

• However, variations in oxytocin receptor genes between people can make oxytocin work differently and less effectively in activating certain brain networks. When those people take MDMA, they experience less of a pro-social effect of the drug.

Serotonin and Dopamine's Role

• The bulk of data points to serotonin increases combined with dopamine increases caused by MDMA as leading to most of the understood effects.

Safety and Potential Neurotoxicity of MDMA

In this section, the speaker highlights important safety concerns regarding recreational use of MDMA and potential neurotoxicity associated with its use.

Recreational Use

• Recreational use of MDMA exploded in popularity during the 1990s Rave culture. It is still illegal to possess or sell.

• Recreational drugs are often contaminated with fentanyl which is highly deadly. Sourcing pure MDMA is extremely important due to safety issues.

Potential Neurotoxicity

• Methamphetamine and MDMA increase dopamine levels which tend to promote electrical activity of other neurons. This can lead to neurotoxicity when large amounts of dopamine are released.

• The brains of people who take methamphetamine degenerate to a smaller or larger degree depending on how often they take the drug, how potent it is, and whether or not they combine it with other drugs.

• Combining caffeine with amphetamines can increase the neurotoxicity of amphetamines such as methamphetamine. Taking caffeine within hours or the same day as MDMA can also increase its toxicity based on animal studies.

Toxicity Studies

In this section, the speaker discusses studies that have been conducted to examine the toxicity of MDMA in humans and animal models.

Animal Studies

• Some animal studies have used dosages of MDMA as high as two milligrams per kilogram of body weight.

• There are a number of results scattered throughout the literature regarding potential neurotoxicity associated with MDMA use in animals and humans.

MDMA and Serotonin: Neurotoxicity in Primates

In this section, the speaker discusses the effects of MDMA on serotonergic tone and how it can lead to reductions in serotonin synthesis pathway proteins. The speaker also talks about how repeated administration of MDMA can lower total amounts of serotonin or dopamine proteins in specific areas of the brain related to reinforcement, mood, and motivation.

Effects of MDMA on Serotonergic Tone

• MDMA encourages or promotes big releases in dopamine and serotonin.

• Animals that have been administered MDMA show reductions in proteins related to the synthesis or release of serotonin.

• Depletion of a neuromodulator in the short term is not the same thing as depletion of that neuromodulator in the long term nor is it the same as loss of neurons that release dopamine and serotonin itself.

Repeated Administration of MDMA

• Repeated administration of MDMA at dosages within 1.5 milligrams per kilogram body weight can lower total amounts of serotonin or other proteins in specific areas of the brain related to reinforcement, mood, and motivation.

• Non-human primate studies suggest that MDMA might not be as neurotoxic as thought based on rodent studies.

• There were some strong suggestions that there was political backing to trying to get a study done quickly and into print regarding severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA.

Study on Severe Dopaminergic Neurotoxicity

• A study published back in 2002 entitled "Severe Dopaminergic Neurotoxicity in Primates After a Common Recreational Dose Regimen of MDMA or Ecstasy" suggested that even recreational doses of ecstasy are neurotoxic to serotonergic and/or dopaminergic neurons.

• The study came under scrutiny for issues of labeling of MDMA versus other drugs in the laboratory, mislabeling, and eventually was retracted by the authors themselves.

• There are studies in rodents showing neurotoxicity of MDMA perhaps even at recreational doses but to date, it is not clear if this translates to humans.

MDMA Neurotoxicity and Cognitive Performance

In this section, the speaker discusses the potential neurotoxicity of MDMA and its effects on cognitive performance. The discussion includes a landmark study that explored the neurocognitive and behavioral effects of taking MDMA.

Landmark Study on Residual Neurocognitive Features of Long-term Ecstasy Users

• People who have taken a lot of MDMA (1 to 200 or sometimes even in excess of 400 doses) were studied to explore the neurotoxicity and neurocognitive effects of taking MDMA.

• A study entitled "Residual Neurocognitive Features of Long-term Ecstasy Users with Minimal Exposure to Other Drugs" confirmed that people were taking pure MDMA and not taking any other drugs is of immense value.

• Moderate users (22 to 50 times in their lifetime) and heavy users (660 to 450 times in their lifetime) showed little evidence of decreased cognitive performance in standard assays for cognitive performance.

• Poor strategic self-regulation was possibly reflecting increased impulsivity, but it's unclear if this is due to ecstasy use or if impulsive people are more likely to take ecstasy.

Lack of Data on Brain Structures

• Unfortunately, there are no data looking at the brains of these individuals looking at for instance which brain structures are active or less active or perhaps even looking at levels of Serotonin or dopamine all things that can be done with positron emission tomography Imaging functional MRI Etc hopefully those studies will be done in the not too distant future.

The Risks of MDMA Use

In this section, the speaker discusses the risks associated with MDMA use and how they can be mitigated.

Neurotoxicity Risk

• The risk for toxicity seems lower than what is often reported in the popular press.

• However, there is still a risk of neurotoxicity if people take high doses of MDMA or take it frequently.

• Taking MDMA in conjunction with other drugs or in settings that promote neurotoxicity can also increase the risk.

Sympathomimetic Effects

• MDMA is a psychostimulant that ramps up activity in the sympathetic nervous system (fight or flight response).

• This leads to increases in blood pressure, heart rate, and body temperature.

• If taken in an environment where temperature regulation is poor, such as at a rave or dance event, neurotoxicity can occur due to increased body temperature.

Importance of Environmental Conditions

• Increases in body temperature can start to kill off neurons.

• Therefore, environmental conditions and behaviors are just as important as the pharmacology of MDMA when considering its potential neurotoxicity.

• Factors such as whether it is pure MDMA or mixed with other substances and whether caffeine has been ingested within 24 hours should also be considered.

Use of MDMA within LDS Community

In this section, the speaker discusses a study on individuals who self-identify as members of the LDS community and their use of MDMA.

Study Findings

• Individuals who self-identify as LDS and have taken MDMA anywhere from 22 to 450 times were studied.

• It is unclear whether this subgroup of the LDS community has officially sanctioned the use of MDMA or if certain individuals have given themselves permission to use it.

Post-MDMA Crash

In this section, the speaker discusses the post-MDMA crash that many people experience after taking the drug.

Myths and Lore

• There are many myths and lore surrounding the post-MDMA crash.

• The speaker does not provide any bullet points for this section.

MDMA and Prolactin

In this section, the speaker discusses the potential neurotoxicity of MDMA and how controlling one's environment can reduce toxicity. The speaker also talks about the crash that occurs after taking MDMA and how it is similar to the crash experienced after taking other stimulants. The increase in prolactin caused by MDMA ingestion is discussed as a possible cause of the post-MDMA crash.

Controlling Environment and Caffeine Intake

• Controlling temperature and restricting caffeine intake before and after MDMA ingestion can reduce potential neurotoxicity.

• Caffeine's effects on dopamine receptors can interact with potential neurotoxicity of MDMA.

Post-MDMA Crash

• The crash experienced after taking MDMA is similar to crashes experienced after taking other stimulants.

• The crash is not due to depletion of serotonin or dopamine, but rather a drop in mood, lethargy, and lack of motivation.

• Taking L-tryptophan or L-tyrosine to recover from the post-MDMA crash has no evidence of being beneficial.

Increase in Prolactin

• Anytime there's a big increase in dopamine, there will be a post-dopominergic increase in prolactin release.

• It is starting to be realized that perhaps it is the increase in prolactin that leads to some components of the post-MDMA crash.

• Some clinicians are exploring the use of p5p which suppresses prolactin as a way to buffer some of that crash.

PTSD and Trauma

In this section, the speaker talks about post-traumatic stress disorder (PTSD) and how it is caused by emotional trauma. The speaker also discusses how MDMA is being explored as a way to augment treatment for PTSD.

Post-Traumatic Stress Disorder

• PTSD is caused by emotional trauma.

• PTSD can be caused by single events such as car accidents or sexual assault.

• MDMA is being explored as a way to augment treatment for PTSD.

Trauma and PTSD Treatment

In this section, the speaker discusses the different forms of trauma that can lead to PTSD. They also recommend a book by Dr. Paul Conti called "Trauma" for those interested in learning more about trauma and its treatment.

Trauma and PTSD

• PTSD can be caused by multiple event traumas, entire relationships, entire childhoods, wartime experiences, combinations of different traumas, etc.

• The book "Trauma" by Dr. Paul Conti is recommended for those interested in learning more about trauma and its treatment.

• The book describes what trauma is and isn't, how it leads to PTSD, and some of Dr. Paul Conti's own experiences with trauma and his own treatment of trauma in his patient population.

• Quality talk therapy has been successful in treating PTSD. It involves good rapport between patient and clinician as well as feelings of support and potential insight.

Talk Therapy for Trauma

• Insight or one's ability to come to an understanding of why one feels the way they do is critical in effective talk therapy for trauma.

• About half of people that undergo talk therapy alone for the treatment of PTSD achieve no long-lasting relief of symptoms.

• Even when ssris are combined with quality talk therapy there's still a large number of people who simply do not achieve significant or long-lasting relief from their PTSD.

Prescription Drug Therapies

• SSRIs have been shown to be effective in limited circumstances for the treatment of PTSD but can have side effects such as blunting libido or appetite disruption.

• There is often an exploration for the so-called minimal effective dose that provides some symptom relief to PTSD but that doesn't introduce unwanted side effects.

• Anytime you add quality talk therapy to a drug treatment, you're going to improve the outcomes for that drug treatment.

MDMA for PTSD Treatment

• Even in people who are getting quality talk therapy and ssris, there's still a large number of people who simply do not achieve significant or long-lasting relief from their PTSD.

• The goal is for somebody to receive treatment that allows them to no longer meet the criteria for having PTSD.

• The whole idea of exploring the use of MDMA for the treatment of PTSD stems from this need.

Symptoms and Comorbidities of PTSD

This section discusses the dissociative symptoms of PTSD, which include brain fog, distraction, sleep issues, and exhaustion. It also highlights that people with PTSD are at a greater risk of substance abuse and other mental health issues such as depression and anxiety.

Symptoms of PTSD

• Dissociative symptoms of PTSD include brain fog, distraction, sleep issues, exhaustion.

• People with either dissociative or non-dissociative symptoms of PTSD are at a greater risk of substance abuse.

• Alcohol use disorder is common in people with PTSD along with opioid use disorder and stimulant use disorder.

• People with PTSD suffer from comorbidities including addiction, depression, anxiety.

Impact on Physical Health

• Cardiovascular and cerebral vascular deficits cause problems in immediate and long-term physical health.

• As many as 8% of people in the United States have PTSD.

• Suicide rates are far greater in people with PTSD than those without it.

How Trauma Affects the Brain

This section explains how trauma affects the brain circuitry leading to changes in neural communication between the brain and body. The insula structure plays a significant role in storing activation of neural circuits related to trauma.

Neural Circuitry Changes due to Trauma

• Trauma causes changes in brain circuitry leading to alterations in neural communication between the brain and body.

• Activation of neural circuits related to trauma centers back into the insula structure that has a map of the body's surface.

• PTSD is caused by heightened levels of activation in brain network circuits such as amygdala to insula pathway and hippocampus to amygdala to insula circuitry.

MDMA as a Treatment for PTSD

This section discusses how MDMA can reduce the levels of activity in the hippocampal to amygdala to insula circuitry, leading to persistent long-lasting reductions in the activation of those brain networks. It also highlights that clinical trials have shown promising results for using MDMA as a valid therapeutic for treating PTSD.

Role of MDMA in Reducing Brain Network Activation

• MDMA can reduce the levels of activity in the hippocampal to amygdala to insula circuitry.

• Clinical trials have shown promising results for using MDMA as a valid therapeutic for treating PTSD.

• The MAPS group has worked with government organizations to get legal authorization to give MDMA along with talk therapy and compare its effects with placebo alone.

Clinical Trials on MDMA-Assisted Therapy for PTSD

This section discusses the clinical trials conducted on MDMA-assisted therapy for PTSD.

Overview of Clinical Trials

• The clinical trials involve giving people talk therapy and either MDMA or placebo.

• The trials aim to relieve both PTSD symptoms and addictive symptoms associated with PTSD.

• When people are given just talk therapy alone or talk therapy with SSRIs, they will often experience reductions in their severity of PTSD symptoms, but rarely complete remittance.

Talk Therapy with MDMA vs Placebo

• People who take part in the clinical trials have already done talk therapy without MDMA before taking it. They then do talk therapy under the influence of MDMA and sessions of talk therapy not under the influence of MDMA, all with the same two therapists.

• In the placebo group, people do talk therapy with two therapists but do not take MDMA.

• Overall rate for clinically effective response to MDMA-assisted therapy is 88%, compared to 60% for placebo and therapy alone.

How Clinical Trials are Conducted

• Patients are selected because they meet the clinical criteria for PTSD and undergo three 90-minute therapy sessions talking about their PTSD symptoms without any drug influence. Then, half are given MDMA while doing three eight-hour sessions of talk therapy with two therapists spaced one week apart after each session. Those in the placebo condition do everything exactly the same as those in the treatment group except they take a placebo instead of MDMA during these sessions.

Success Rates

• 67% of people in the treatment group no longer met criteria for PTSD by the end of treatment, compared to 23% in the placebo group.

• The success rate for clinically effective response to MDMA-assisted therapy is 88%, compared to 60% for placebo and therapy alone.

Therapy Sessions

• During MDMA sessions, patients have therapists present with whom they talk about their trauma while spending time with their eyes closed lying down sometimes in an eye mask and thinking about the trauma, current state, and experience. They also undergo three 90-minute therapy sessions with two therapists spaced one week apart after the final MDMA session.

The Effectiveness of MDMA in Treating PTSD

In this section, the speaker discusses the effectiveness of MDMA in treating PTSD and other co-morbid disorders.

MDMA Plus Talk Therapy Treatment

• An 88% success rate has been observed for the treatment of major psychiatric disorders with a significant reduction in clinical symptoms for PTSD.

• The potential transition of MDMA from a schedule one drug to a legal context of clinical use application is being considered by the legislature as early as 2023 or 2024.

• People who were treated with MDMA plus talk therapy showed resolution of their addiction to alcohol or other substances.

Results from Clinical Trials

• Successful treatment of PTSD almost always involves getting close to or reporting traumatic experiences in detail, which can be difficult for people with dissociative forms of PTSD.

• Patients with PTSD who received MDMA plus talk therapy were able to get close to their traumatic experiences and reframe them in a context that often involved empathy for others and self.

• Emotional load seems diminished both within the MDMA treatment session and afterwards for long periods of time.

Overall, this section highlights how effective MDMA can be when used in combination with talk therapy to treat PTSD and other co-morbid disorders. It also emphasizes how patients are able to reframe their traumatic experiences through empathy for themselves and others.

MDMA and Talk Therapy for PTSD Treatment

In this section, the speaker discusses the clinical trials conducted by MAPS on the combination of MDMA and talk therapy for treating PTSD, depression, alcohol use disorder, and eating disorders. The speaker explains how MDMA produces a neurochemical milieu in the brain that enhances the effectiveness of talk therapy.

MDMA's Effect on Talk Therapy

• The combination of MDMA and talk therapy is not about the drug having a particular effect but rather about allowing talk therapy to be more effective.

• MDMA produces a subjective and neurochemical milieu in the brain that allows therapy to be more potent within a limited number of sessions.

• The cost of mental health care can be reduced with this treatment as people who are suffering from PTSD, depression or addiction can achieve relief in fewer sessions.

• Under the influence of MDMA in safe and therapeutic settings, patients are able to look at traumatic events and reframe them cognitively and somatically.

Adverse Effects

• There were no increases in suicide attempts or suicidality associated with using MDMA drug therapy for PTSD treatment.

• Adding MDMA drug therapy to PTSD talk therapy does not seem to increase side effects associated with exploring PTSD and trauma.

Exciting Times for Mental Health Community

• It is exciting times for exploring compounds like MDMA as an augmented talk therapy for treating mental health issues such as PTSD, depression, alcohol use disorder, and eating disorders.

• When used properly under safety protocols with clinical support, combining quality talk therapy with MDMA has tremendously positive outcomes.

MDMA: A Clinical Tool for Psychiatric Disorders

In this section, the speaker talks about MDMA and its potential as a clinical tool for treating psychiatric disorders like PTSD and addiction. The speaker also discusses the neurotoxicity issues associated with MDMA and emphasizes the importance of caution when using any sympathomimetic drug.

MDMA: An Incredible Compound

• MDMA is a compound synthesized by humans that produces big increases in dopamine and serotonin to create highly motivated pro-social empathic states.

• When applied in the context of psychiatric challenges like PTSD and addiction, it is proving to create relief where other forms of drug therapy or combination drug and talk therapy had failed before.

Neurotoxicity Issues Associated with MDMA

• At reasonable doses when not combined with other drugs, it does not appear that MDMA is exceedingly neurotoxic, and it may not be neurotoxic at all.

• However, one needs to be exceedingly cautious when thinking about the use of any sympathomimetic drug because they can be neurotoxic. Anything with methamphetamine in it has a potential to be neurotoxic.

• The purity of the drug matters, and fentanyl contamination of MDMA sold on the street is a serious potentially lethal concern.

Importance of Clinical Trials

• There will likely be a lot of interest in clinical trials that MAPS (Multidisciplinary Association for Psychedelic Studies) is doing.

• We are at an interesting time in human history for the treatment of psychiatric disorders because we are discovering new ways to access neuroplasticity through talk therapy and drug therapies.

Conclusion

• MDMA is an incredibly interesting and important topic for the treatment of psychiatric disorders, and it has the potential to create relief where other forms of therapy have failed.

• If you're interested in learning more about science-related tools for mental health, physical health, and performance, follow the speaker on social media or subscribe to their newsletter.